ITPK5 Antibody

What are the key differences between ITPKB and ITPKC antibodies?

ITPKB (Inositol 1,4,5-trisphosphate 3-kinase B) and ITPKC (Inositol 1,4,5-trisphosphate 3-kinase C) antibodies target different isoforms of the ITPK enzyme family. While both isoforms catalyze the phosphorylation of Ins(1,4,5)P3 to Ins(1,3,4,5)P4 and contain conserved catalytic units in their C-termini, they differ in their N-terminal sequences and tissue distribution patterns . ITPKB plays crucial roles in immune cell development, while ITPKC is involved in calcium homeostasis modulation. When selecting between these antibodies, researchers should consider their specific target tissues and the isoform expression patterns relevant to their experimental models.

What applications are validated for ITPKB antibodies?

ITPKB antibodies have been validated for multiple applications, including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA. According to published literature, ITPKB antibodies show reactivity with human, mouse, and rat samples . For Western Blot applications, the recommended dilution ranges from 1:500 to 1:1000, while for IHC applications, dilutions between 1:20 and 1:200 are suggested. The antibody has been successfully used in knockout/knockdown validation studies, with positive Western Blot detection in mouse brain tissue, K-562 cells, mouse lung tissue, mouse thymus tissue, and rat brain tissue .

How should researchers store and handle ITPK antibodies to maintain reactivity?

Proper storage and handling of ITPK antibodies are critical for maintaining their reactivity and performance. According to product specifications, these antibodies are typically stored in PBS buffer containing 0.02% sodium azide and 50% glycerol at pH 7.3 . They should be stored at -20°C, where they remain stable for one year after shipment. For lyophilized antibody formats, such as the Anti-Integrin alpha 5/ITGA5 Antibody, reconstitution is required before use, after which they can be stored at 4°C for one month . For long-term storage of reconstituted antibodies, aliquoting and freezing at -20°C is recommended for up to six months. Repeated freeze-thaw cycles should be avoided as they can degrade antibody quality and reduce reactivity .

How can I determine the optimal working concentration for blocking experiments with integrin antibodies?

When designing blocking experiments with integrin antibodies such as anti-ITGA5, determining the optimal working concentration requires careful titration. As noted in manufacturer responses to researcher queries, "The application varies so we recommend to determine the optimum working dilution of the product that is appropriate for a specific need" .

For VLA5-mediated function inhibition experiments, consider the following approach:

• Perform a preliminary dose-response experiment using a wide concentration range (e.g., 0.1-10 μg/ml)

• Assess functional readouts specific to your experimental system

• Include appropriate isotype controls to account for non-specific effects

• For cell culture applications, test antibody stability in your specific culture medium

• If targeting extracellular domains, consider using F(ab')₂ fragments to avoid Fc receptor-mediated effects

Remember that blocking efficiency may vary depending on target cell types and experimental conditions, requiring optimization for each specific application .

What controls should be included when validating antibody specificity in immunohistochemistry experiments?

Validating antibody specificity in immunohistochemistry requires rigorous controls to ensure reliable results:

As evidenced in the validation of Anti-ITGA5 antibody, proper antigen retrieval (heat-mediated in EDTA buffer, pH 8.0) and appropriate blocking (10% goat serum) are critical for specificity, as are incubation conditions (overnight at 4°C for primary antibody, 30 minutes at 37°C for secondary) .

How should researchers design experiments to measure antibody-induced platelet desialylation and apoptosis?

Based on recent research methodologies, experiments to measure antibody-induced platelet desialylation and apoptosis should be designed with the following considerations:

• Sample preparation:

  • Isolate washed platelets from healthy donors

  • Treat platelets with test sera (e.g., from ITP patients) or purified IgG fractions

  • Include appropriate controls (healthy donor sera/IgG)

• Key measurements:

  • Neuraminidase 1 (NEU1) surface expression using specific antibodies

  • RCA-1 lectin binding to detect desialylation

  • Mitochondrial inner membrane potential (ΔΨm) loss using DiOC₆ fluorescence to assess apoptosis

• Analytical approach:

  • Use flow cytometry for quantitative assessment

  • Compare antibody-positive vs. antibody-negative samples

  • Analyze the effects of different antibody specificities (e.g., anti-GPIIb/IIIa vs. anti-GPIb/IX)

• Mechanistic investigations:

  • Test FcγRIIa dependency using blocking antibodies

  • Assess the role of platelet activation using activation inhibitors

  • Consider in vivo validation using murine models

This experimental design provides a comprehensive approach to study the pathophysiological mechanisms of antibody-mediated platelet destruction.

How should researchers analyze and report flow cytometry data when evaluating antibody binding?

When analyzing flow cytometry data for antibody binding studies, researchers should follow these methodological guidelines:

• Gating strategy:

  • Implement sequential gating to exclude debris, doublets, and dead cells

  • Dead cells often non-specifically absorb antibodies, leading to false positives

• Quantitative reporting:

  • For population frequency changes: Report percentage of positive cells

  • For expression level changes: Use Median Fluorescence Intensity (MFI) rather than mean for log-transformed data

• Data normalization and comparison:

  • Calculate fold-change in MFI = MFI(sample)/MFI(control)

  • Be cautious when interpreting small changes in negative populations, as log scale can skew fold-change values

  • Standardize assays using reference standards (e.g., Rainbow Beads) for PMT sensitivity to enable comparison across experiments run on different days

• Statistical considerations:

  • Apply appropriate statistical tests for non-normally distributed data

  • Include biological replicates to account for donor variability

  • Use matched statistical tests for paired samples when appropriate

• Data visualization:

  • Present both representative flow plots and quantitative summaries

  • Include error bars representing biological variation

What approaches can be used to interpret contradictory antibody binding results across different tissue samples?

When facing contradictory antibody binding results across different tissue samples, researchers should employ a systematic approach to resolve these discrepancies:

• Technical validation:

  • Confirm antibody lot consistency and performance using standard samples

  • Verify protocol adherence across experiments (fixation methods, antigen retrieval, blocking solutions)

  • Assess tissue preparation variables (fixation time, processing methods)

  • Re-evaluate antibody dilution and incubation conditions for each tissue type

• Biological considerations:

  • Examine target protein expression levels across tissues (using orthogonal methods)

  • Consider tissue-specific post-translational modifications affecting epitope accessibility

  • Evaluate potential cross-reactivity with related proteins expressed in different tissues

  • Account for tissue-specific microenvironments that might affect antibody penetration

• Analytical strategies:

  • Implement epitope mapping to identify binding sites

  • Use multiple antibodies targeting different epitopes of the same protein

  • Compare results with genetic validation (knockout/knockdown controls)

  • Employ orthogonal detection methods (e.g., RNA expression, mass spectrometry)

• Reporting recommendations:

  • Document all experimental conditions thoroughly

  • Present both positive and negative results with appropriate controls

  • Discuss potential reasons for discrepancies based on known biology

  • Consider consulting antibody manufacturers for technical support, as demonstrated in customer Q&A examples

How can pharmacokinetic modeling be applied to analyze monoclonal antibody distribution and clearance in first-in-human studies?

Pharmacokinetic modeling provides a powerful framework for analyzing monoclonal antibody distribution and clearance in first-in-human studies:

• Model selection and development:

  • A 2-compartment model with first-order elimination from the central compartment has been shown to robustly fit combined data from multiple monoclonal antibodies

  • For subcutaneous administration, include a depot compartment with first-order absorption

• Parameter estimation approach:

  • Use population pharmacokinetic (popPK) modeling to account for inter-subject variability

  • Typical parameter estimates for linear mAbs: systemic clearance ~0.20 L/day, central volume of distribution ~3.6 L

  • Account for inter-subject variability (31% for clearance, 34% for volume of distribution)

  • Apply proportional residual error model (typically around 14%)

• Study design optimization:

  • Implement stochastic simulation and estimation to compare sampling designs:

    • Rich designs (22 samples/subject): Comprehensive but resource-intensive

    • Minimal designs (5 samples/subject): Sufficient for basic popPK

    • Optimal designs (10 samples/subject): Balance between resources and quality for both non-compartmental analysis and popPK

• Applications to research questions:

  • Compare parameters across antibody isotypes (e.g., IgG1 vs. IgG2)

  • Assess linearity of elimination across dose ranges

  • Evaluate bioavailability differences between administration routes

  • Predict optimal dosing schedules for subsequent clinical studies

This modeling approach enables efficient first-in-human study designs while providing robust pharmacokinetic parameter estimates for therapeutic antibody development .

How can computational methods be integrated into antibody design for improved specificity and developability?

Integration of computational methods into antibody design represents a cutting-edge approach for enhancing both specificity and developability:

• Combined AI and physics-based methods:

  • Recent research demonstrates successful integration of both approaches in end-to-end antibody design pipelines

  • This combination improves productivity and viability of antibody designs through efficient few-shot experimental screens

• Biophysics-informed modeling for specificity engineering:

  • Utilize models trained on experimentally selected antibodies to identify distinct binding modes associated with specific ligands

  • This approach enables prediction and generation of specific variants beyond those observed in experiments

  • Successfully applied to distinguish binding preferences even between chemically similar epitopes

• Sequence-structure-function relationships:

  • Apply large-scale paired antibody language models (e.g., IgBert and IgT5) for superior performance in antibody design tasks

  • These models can handle both paired and unpaired variable region sequences as input

  • Training on billions of sequences enables better understanding of sequence-function relationships

• Validation through iterative design cycles:

  • Experimentally test computational designs against multiple targets

  • Validate designs through binding assays, developability profiles, and structural studies

  • Apply the approach to rescue binding from escape mutations (demonstrating up to 54% of designs gaining binding affinity to new variants)

This integrated approach has been successfully applied to identify highly sequence-dissimilar antibodies that retain binding properties, rescue binding to escape variants, and improve developability characteristics while maintaining target recognition .

What are the mechanisms behind antibody agonism versus antagonism, and how can this knowledge inform therapeutic development?

Understanding the mechanisms distinguishing antibody agonism from antagonism provides critical insights for therapeutic development:

• Mechanism of antibody agonism:

  • Recent research reveals that agonistic antibodies trigger immune receptor signaling through local exclusion of inhibitory phosphatases

  • Specifically, antibody agonists sterically exclude large receptor-type protein tyrosine phosphatases (RPTPs) such as CD45 from sites of receptor engagement

  • This exclusion is dependent on:

    • Antibody immobilization

    • Size relationships between the receptor, RPTPs, and the antibody itself

    • Binding location on the target receptor

• Key determinants of functional outcome:

  • Binding location: Membrane-proximal binding enhances phosphatase exclusion

  • Antibody orientation: Affects the spatial arrangement of immune synapses

  • Target receptor characteristics: Size and signaling mechanism influence response

  • Immobilization status: Soluble versus immobilized antibodies can produce opposite effects

• Paradoxical effects in clinical antibodies:

  • Some blocking antibodies (e.g., nivolumab and pembrolizumab) can exhibit unexpected agonistic effects in certain contexts

  • This explains some contradictory clinical observations and potential side effects

• Applications to therapeutic design:

  • Engineer antibodies with reduced agonistic effects for improved PD-1 blockade

  • Design membrane-proximal binding antibodies for enhanced agonism of stimulatory receptors

  • Consider antibody format (Fab, F(ab')₂, IgG) based on desired functional outcome

  • Evaluate immobilization status in the target tissue microenvironment

This mechanistic understanding provides a framework for developing new and improved immunotherapies for autoimmunity and cancer.

How can BTK inhibitors enhance bispecific antibody efficacy in cancer immunotherapy?

BTK inhibitors (BTKis) can significantly enhance bispecific antibody efficacy in cancer immunotherapy through several key mechanisms:

This research provides a rationale for combining BTKis with bispecific antibody immunotherapy to deepen responses, shorten treatment duration, and potentially overcome drug resistance in CLL patients.

What strategies can resolve non-specific binding issues in Western blot applications using anti-ITGA5 antibodies?

Resolving non-specific binding issues with anti-ITGA5 antibodies in Western blot requires systematic optimization:

• Blocking optimization:

  • Test different blocking agents (5% non-fat milk, 5% BSA, commercial blocking buffers)

  • Extend blocking time (1-2 hours at room temperature or overnight at 4°C)

  • Consider tissue-specific blocking optimization (e.g., liver tissue may require different conditions)

• Antibody dilution and incubation:

  • Titrate antibody concentration beyond manufacturer's recommended range (1:500-1:2000)

  • Extend primary antibody incubation time (overnight at 4°C instead of 1-2 hours)

  • Optimize secondary antibody dilution independently

  • Include 0.05% Tween-20 in antibody diluent to reduce background

• Washing protocol optimization:

  • Increase washing duration and frequency (5-6 washes of 5-10 minutes each)

  • Use TBS-T (Tris-buffered saline with 0.1% Tween-20) for more stringent washing

  • Consider adding low concentrations of SDS (0.01-0.05%) to washing buffer for high-background samples

• Sample preparation considerations:

  • Optimize protein extraction methods for specific tissues (e.g., liver requires specific protocols)

  • Include protease inhibitors during extraction to prevent degradation

  • Ensure complete protein denaturation and reduction

  • Consider membrane pore size selection based on target protein size

• Validation approaches:

  • Use a blocking peptide as mentioned in customer Q&A to confirm specificity

  • Consider pre-absorbing the antibody with non-specific proteins

  • Include appropriate positive and negative control tissues

  • Try different detection systems (chemiluminescent, fluorescent) to optimize signal-to-noise ratio

What factors influence the success of antibody-based immunotherapy in resistant cancer types?

Several critical factors influence the success of antibody-based immunotherapies in traditionally resistant cancer types:

• Immune cell recruitment strategies:

  • Target alternative immune cells beyond T cells, such as natural killer (NK) cells

  • Recent research demonstrates significant tumor shrinkage in lung cancer models resistant to T-cell-based therapies by engaging NK cells

  • Consider antibody designs that activate multiple immune cell populations simultaneously

• Genetic determinants of resistance:

  • Identify genetic signatures of resistance (e.g., KRAS and LKB1 mutations in non-small cell lung cancer)

  • Select appropriate target antigens expressed in resistant tumors

  • Develop antibodies targeting resistance-specific surface markers

• Antibody engineering considerations:

  • Format selection (IgG, bispecific, antibody-drug conjugates)

  • Fc engineering to enhance immune effector functions

  • Epitope targeting to avoid resistance mechanisms

  • Affinity optimization for tumor penetration versus on-target/off-tumor effects

• Combination therapy approaches:

  • Pair antibodies with immune checkpoint inhibitors

  • Combine with targeted therapies addressing resistance mechanisms

  • Consider sequential versus concurrent administration

  • Evaluate synergy with conventional therapies (chemotherapy, radiation)

• Biomarker-guided patient selection:

  • Develop predictive biomarkers for response

  • Consider tumor microenvironment characteristics

  • Assess baseline immune infiltration patterns

  • Monitor dynamic changes during treatment

Recent work has shown success with novel strategies, such as targeting proteins like MICA and MICB to activate NK cells against tumors that are resistant to conventional immune checkpoint inhibitors .

How can researchers validate antibody epitope specificity when targeting closely related protein isoforms?

Validating antibody epitope specificity for closely related protein isoforms requires a multi-faceted approach:

• Computational epitope prediction and testing:

  • Apply biophysics-informed models to identify distinct binding modes for similar ligands

  • Generate and test antibody variants predicted to differentiate between closely related epitopes

  • Utilize machine learning approaches to predict cross-reactivity based on sequence similarity

• Advanced experimental validation techniques:

  • Epitope binning using bio-layer interferometry or surface plasmon resonance

  • Hydrogen/deuterium exchange mass spectrometry to map epitope boundaries

  • X-ray crystallography or cryo-EM for structural confirmation of binding interfaces

  • Alanine scanning mutagenesis to identify critical binding residues

• Cross-reactivity assessment:

  • Test against panels of recombinant isoforms at varying concentrations

  • Evaluate binding to target proteins from multiple species to assess conservation

  • Perform competitive binding assays with known ligands or antibodies

  • Assess binding to knockout/knockdown cell lines for each isoform

• Functional validation approaches:

  • Compare functional effects on distinct isoforms (e.g., ITPKB vs. ITPKC)

  • Evaluate signaling pathway activation specific to each isoform

  • Assess inhibition of catalytic activities for enzymatic targets

  • Confirm specificity in cellular contexts with defined isoform expression patterns

• Documentation and reporting:

  • Clearly document epitope regions when known

  • Specify exact binding conditions that differentiate isoforms

  • Report both positive and negative binding results across related proteins

  • Consider developing specialized reference materials for validation

This comprehensive approach ensures reliable differentiation between closely related isoforms, critical for both basic research and therapeutic applications.